$14.590
+0.286 (+1.96%)Zum Schluss
AFYA-News
AFYA-Events
Afya and Yduqs Discuss Potential Business Combination
Afya Limited announced that discussions with Yduqs Participacoes regarding a potential business combination involving the two companies are at an early stage, following the material fact disclosed by Yduqs on this date. As disclosed by Yduqs, these discussions remain at an early stage, and there can be no assurance that they will result in any agreement or transaction. To date, no binding agreement, contract, or commitment has been entered into, nor has any obligation been assumed, by Afya, Yduqs, or any of their respective shareholders or management teams in connection with any potential transaction.
Afya announces Q3 adjusted EBITDA of R$398.9M, a 14.6% increase year-over-year
Reports Q3 revenue R$928.5M, or R$926.2M excluding acquisitions, vs. R$841.2M last year. Company management stated: "This quarter demonstrates once again Afya's ability to combine transformation with financial discipline. We advanced in initiatives that strengthen our ecosystem, and accelerate innovation, while maintaining a prudent approach to capital allocation. These achievements reinforce our confidence in the strategy and our capacity to deliver sustainable growth and long-term value for all stakeholders. We saw steady advances across our three segments, reflecting our commitment to integrate education and medical practice solutions throughout the medical journey. In Undergraduate, we concluded another intake cycle, ensuring full occupancy across all our medical schools, which reinforces Afya's differentials and the ability to attract and retain top candidates nationwide. This approach ensures consistency in admissions, strengthens our brand positioning, and optimizes operational efficiency. In Continuing Education, we sustained impressive growth in B2B Revenue, while strengthening the graduate journey. In Medical Practice Solutions we achieved a notable increase in active payers within Clinical Management, reinforcing the value of our solutions in supporting physicians' daily practice. Our ecosystem continues to enhance learning outcomes and employability, strengthening our reputation within the medical community. We advanced AI-enabled enhancements to Afya Whitebook, iClinic and ReceitaPro further supporting clinical productivity and evidence-based decision-making at the point of care. In parallel, we launched Instituto Afya, aligned with the UN 2030 Agenda to address chronic disease challenges. Together, these initiatives strengthen our ecosystem and support long-term value creation. During October, we took coordinated actions to strengthen our capital structure. We issued commercial notes totaling R$1.5 billion in two series, maturing in 2028 and 2030, with interest rates of CDI+0.70% and CDI+0.85% per year, respectively. Using the proceeds, we repurchased all 150,000 Series A perpetual convertible preferred shares from SoftBank for R$831.6 million and fully repaid R$500 million related to Afya Participacoes first debenture issuance. These actions extend debt duration, and reinforce our disciplined approach to capital management. Looking ahead, we remain confident in our ability to keep delivering sustainable growth. Our integrated ecosystem, operational excellence and innovation agenda position Afya to execute with quality and consistency. We reaffirm our 2025 guidance and are proud of the progress achieved so far - energized by the opportunities ahead as we continue to transform the medical journey and physician career success in Brazil."
Afya Reveals Expansion of Medical Seats at ITPAC Porto Nacional
Afya announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education authorized the increase of 100 medical seats of ITPAC Porto Nacional - Instituto Tocantinense Presidente Antonio Carlos Porto S.A., in the city of Braganca, located in the state of Para. With the authorization, Afya reaches 150 medical seats on this campus, and 3,753 total approved seats. This significant presence underscores our commitment to providing quality medical education and our role as a leading medical education group in Brazil.
Afya still sees 2025 revenue R$3.67B-R$3.77B
Still sees 2025 adjusted EBITDA R$1.62B-R$1.72B and CapEx R$250M-$290M.
Afya reports Q2 EPS R$2.27 vs. R$2.29 last year
Reports Q2 revenue R$919.4M, or R$879.0M excluding acquisitions, vs. R$809.9M last year. Company management stated, "We are pleased to report that Afya continues to deliver strong operational and financial results...This quarter was marked by significant revenue growth and gross margin expansion in both our Undergraduate and Continuing Education segments, reflecting the steady expansion of our business and our ongoing commitment to operational excellence. We are also pleased to reaffirm that Afya remains on track to meet our full-year 2025 guidance, supported by disciplined execution and strong business fundamentals. Once again, we delivered a strong performance, closing the first half of 2025 with a notable increase in Adjusted EBITDA Margin, reaching 48.1%...With the closing of the acquisition of Funic, a campus that will begin its operation in the second half of 2025, we are pleased to reinforce our solid market position by expanding our undergraduate footprint into the metropolitan area of Belo Horizonte, capital of Minas Gerais. This acquisition adds 60 new medical seats, bringing Afya's total number of approved medical seats to 3,653 as of today. our Board of Directors approved a new share repurchase program. This initiative authorizes the repurchase of up to 4M Class A shares...Our commitment to innovation and excellence drives us to keep enhancing the medical journey at every stage".
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.





